Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of multiple dosages of
INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis
(CF) lung disease. Study drug will be administered through a nebulizer (a device that
delivers medication as a mist by breathing it in).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics